David Scott Nunn

Title: David Scott Nunn: Innovator in Therapeutic Compounds

Introduction: David Scott Nunn is a notable inventor based in Valley Cottage, NY (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific receptors in the brain. His work is essential for advancing therapeutic treatments for various disorders.

Latest Patents: David Scott Nunn holds a patent for "Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands." This invention provides a compound of formula I and outlines its use for the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. This patent highlights his innovative approach to addressing complex medical challenges.

Career Highlights: Nunn is currently associated with Wyeth, a prominent pharmaceutical company known for its research and development in healthcare. His role at Wyeth allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations: Throughout his career, David has worked alongside talented individuals such as Derek Cecil Cole and Michael G Kelly. These collaborations have fostered an environment of innovation and have led to the development of impactful therapeutic solutions.

Conclusion: David Scott Nunn's contributions to the field of medicinal chemistry and his innovative patent demonstrate his commitment to improving therapeutic treatments. His work continues to influence the development of new medications that can enhance patient care.